INVIVYD, INC. (IVVD) Current Ratio
- Current ratio · latest quarter: Value 5.87×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 5.87× | Current assets / current liabilities. $182.11M ÷ $31.03M ≈ 5.87× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 182.11M USD | Assets, Current |
| Current obligations | 31.03M USD | Liabilities, Current |
| Cash and equivalents | 160.08M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 11.22M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | Inventory, Net |
| Payables | 9.49M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $182.11M | $31.03M | $160.08M | (m) | $11.22M | (m) | $9.49M | (m) | 5.87× |
| 2026-03-31 | $204.91M | $31.66M | $184.15M | (m) | $11.65M | (m) | $2.02M | (m) | 6.47× |
| 2025-12-31 | $247.47M | $34.16M | $226.69M | (m) | $13.92M | (m) | $13.74M | (m) | 7.24× |
| 2025-09-30 | $109.77M | $44.50M | $84.97M | (m) | $9.85M | $25.39M | $18.10M | (m) | 2.47× |
| 2025-06-30 | $59.28M | $44.45M | $34.91M | (m) | $8.70M | $25.44M | $18.05M | (m) | 1.33× |
| 2025-03-31 | $75.83M | $49.59M | $48.08M | (m) | $8.56M | $25.42M | $8.74M | (m) | 1.53× |
| 2024-12-31 | $100.68M | $61.98M | $69.35M | (m) | $10.91M | (m) | $10.45M | (m) | 1.62× |
| 2024-09-30 | $151.10M | $78.54M | $106.87M | (m) | $8.15M | $27.07M | $17.71M | (m) | 1.92× |
| 2024-06-30 | $173.01M | $36.70M | $147.88M | (m) | $2.89M | $5.33M | $7.50M | (m) | 4.71× |
| 2024-03-31 | $209.88M | $36.34M | $189.39M | (m) | (m) | $109.00K | $1.17M | (m) | 5.77× |
| 2023-12-31 | $224.88M | $50.29M | $200.64M | (m) | $0.00 | $0.00 | $7.95M | (m) | 4.47× |
| 2023-09-30 | $270.10M | $26.79M | $181.82M | (m) | (m) | (m) | $9.17M | (m) | 10.08× |
| 2023-06-30 | $309.99M | $32.51M | $121.95M | (m) | (m) | (m) | $4.11M | (m) | 9.54× |
| 2023-03-31 | $344.62M | $22.06M | $126.47M | (m) | (m) | (m) | $5.91M | (m) | 15.62× |
| 2022-12-31 | $376.92M | $25.03M | $92.08M | (m) | (m) | (m) | $1.52M | (m) | 15.06× |
| 2022-09-30 | $421.60M | $46.13M | $278.15M | (m) | (m) | (m) | $16.77M | (m) | 9.14× |
| 2022-06-30 | $481.36M | $67.88M | $474.88M | (m) | (m) | (m) | $14.23M | (m) | 7.09× |
| 2022-03-31 | $554.30M | $95.53M | $532.22M | (m) | (m) | (m) | $18.68M | (m) | 5.80× |
| 2021-12-31 | $616.71M | $62.06M | $542.22M | (m) | (m) | (m) | $5.78M | (m) | 9.94× |
| 2021-09-30 | $680.15M | $53.05M | $478.27M | (m) | (m) | (m) | $17.56M | (m) | 12.82× |
| 2021-06-30 | $396.06M | $37.90M | $392.51M | (m) | (m) | (m) | $10.72M | (m) | 10.45× |
| 2020-12-31 | $117.38M | $13.07M | $114.99M | (m) | (m) | (m) | $8.15M | (m) | 8.98× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |